Aglaia Oncology Funds
Eric van der Putten has an extensive background in the field of oncology drug development and clinical trials. With experience in various companies and roles such as Non-Executive Director at MIMETAS, Director at Modra Pharmaceuticals, and Partner at Aglaia Oncology Funds, Eric specializes in advancing innovative therapies for cancer treatment. Eric's previous positions include Co-founder at SMS-oncology and Vice President Oncology Europe at INC Research Netherlands BV. Eric holds a BSc in Biochemistry/Immunology and a BSc in Pathology/Histology from HBO-university Amsterdam.
This person is not in any teams
Aglaia Oncology Funds
Aglaia is an investment fund fully focused on the fight against cancer and the development of improved anti-cancer drugs in particular. Aglaia has a proven ability to select and mature early-stage breakthrough inventions that have the potential to transform cancer treatment. For more information, please visit www.aglaia-oncology.com